INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data due in late 2024

About this update from Initiator Pharma A/s

Pudafensine is advancing in late-stage clinical trials for both erectile dysfunction and vulvodynia, targeting large unmet needs with a unique dual mechanism and strong safety profile. Partnering discussions are intensifying, with key data readouts expected by year-end 2024.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Initiator Pharma A/s